BMS-984923
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
2
Sites
3
Countries
1
Endpoints
28
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 28 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 4 of 28 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT05804383A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease | BMS-984923 Alzheimer’s disease | MoCA ≥25 | Ph 1 | Completed | 2 | Jul 2025 | 2 | |
| NCT05817643Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers | BMS-984923 Alzheimer’s disease | Age 50-80 | Ph 1 | Unknown | 1 | Feb 2023 | - | |
| NCT04805983Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923 | BMS-984923 Alzheimer’s disease | Study partner/caregiver required | Ph 1 | Completed | 1 | Apr 2022 | - | results |
Showing 1-3 of 3 trials